Tag: Tucatinib

Tukysa, a targeted therapy approved by the FDA in 2020 for certain HER2-positive cancers, is more formally known by its generic name, tucatinib. This oral medication works as a kinase inhibitor to block signaling pathways that promote cancer cell growth, and it is crucial for patients and clinicians to understand its multiple identifiers for accurate treatment management.

Clinical trials show that correct administration of tucatinib is vital, with nearly everyone experiencing some side effects, including 22% reporting serious ones, emphasizing the need for patient education. Understanding **how is tucatinib administered** correctly is essential for maximizing its therapeutic benefits and ensuring patient safety throughout the treatment regimen.